Business Information
The group's principal activities are to develop, manufacture and market drug delivery systems employing iontophoresis technology. It currently markets two iontophoretic products, the phoresor (r ) and numby stuff (r). The group's products are used in situations when it is advisable to avoid the pain that may accompany needle insertion and drug injection, and/or to minimize the infiltration of carrier fluids, or to avoid the damage caused by needle insertion when tissue is traumatized. Its patented iontophoresis system, the phoresor (R), is designed for clinical use and is comprised of a reusable dose controller and single use, disposable active transdermal patch kits. The dose controller incorporates an advanced microprocessor to precisely control drug dosage through single-use, disposable patch kits, including its iogel(R), transq(R) and anestrode(R) patch kits.
|
|
Name |
Title
|
Email
|
| Peter Wardle | Chmn. | N/A | | Brian Mower | CFO | N/A | | Mary Crowther | VP - Administrative Services, Sec. | N/A | | Curtis Jensen | Dir. - Quality, Regulatory Affairs | N/A | | James Cronkrite | Dir. - Manufacturing | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 10,843 | 600 | | 2005 | 11,426 | 425 | | 2004 | 12,189 | 954
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
